Patients with a high-risk CD8-associated gene signature and worse OS had a higher tumor immune dysfunction and exclusion (TIDE) score, along with low inhibitory receptor expression, TMB, and MSI, suggesting limited benefit from ICB therapy. This evidence concerns the gene CD8A and neoplasm.